Kezar Life Sciences, Inc.

  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
  • Pipeline
    • Overview
    • KZR-616
    • KZR-261
  • Our Science
    • Overview
    • Medical & Scientific Presentations
    • Publications
  • Clinical Trials
  • Investors & News
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact Us

Medical & Scientific Presentations

Our Science

Our Science

  • Overview
  • Medical & Scientific Presentations
  • Publications
Apr 2, 2019

Discovery and Characterization of Novel Anti-Cancer Small Molecule Inhibitors of Sec61

Kezar Life Sciences, Inc.

Nov 6, 2018

Pharmacokinetics, Pharmacodynamics, and Their Relationship of KZR-616 in Healthy Volunteers

Kezar Life Sciences, Inc.

Nov 5, 2018

Role of Epoxide Hydrolases and Cytochrome P450s on Metabolism of KZR-616, a First-in-Class Selective Inhibitor of the Immunoproteasome

Kezar Life Sciences, Inc.

Nov 4, 2017

Selective Inhibition of the Immunoproteasome Subunit LMP7 is Not Sufficient for Blocking Cytokine Production or Attenuating Progression of Experimental Arthritis

Kezar Life Sciences, Inc.

Nov 4, 2017

KZR-616 Blocks Disease Progression in Multiple Models of SLE

Kezar Life Sciences, Inc.

Nov 4, 2017

KZR-616 Shows Promising Safety and Target Inhibition Profile

Kezar Life Sciences, Inc.

RSS
  • « Previous
  • 1
  • 2
  • 3
Kezar Life Sciences, Inc.
  • About Us
  • Pipeline
  • Our Science
  • Clinical Trials
  • Investors & News
  • Careers
Contact Us

4000 Shoreline Court , Suite 300
South San Francisco, CA 94080

Linkedin Facebook Twitter YouTube

© 2021 Kezar Life Sciences, Inc. All Rights Reserved.

Privacy Policy Disclaimer Sitemap